Researchers have tested more than 680 million substances on the computer to virtually test one of the virus’ important proteins, the central protease

Picture: University of Basel, Computational Pharmacy

News • Computer-aided search for substances

Virtual screening for anti-coronavirus drugs

The University of Basel is part of the global search for a drug to fight the rampant coronavirus SARS-CoV-2.

Researchers in the Computational Pharmacy group have so far virtually tested almost 700 million substances, targeting a specific site on the virus – with the aim of inhibiting its multiplication. Due to the current emergency, the first results of the tests will be made available to other research groups immediately.

The results so far have been published in ChemRxiv.

To be prepared for future coronavirus outbreaks

This will make it possible to nip health crises like this one in the bud in the future

Markus Lill

Over the past few weeks, the research group in the Department of Pharmaceutical Sciences, led by Professor Markus Lill, has been working with computer-aided methods to identify possible new drugs to combat the current coronavirus outbreak and similar epidemics in the future. In the process, the researchers have tested, albeit virtually, more than 680 substances on one of the virus’s key proteins: its central protease.

This “virtual screening” has already identified several interesting substances that have the potential to inhibit the virus’s critical enzyme – and thus its further multiplication. “Even if the complete development of a drug to fight this particular coronavirus is likely to exceed the duration of the current epidemic, it is important to develop drugs for future coronaviruses. This will make it possible to nip health crises like this one in the bud in the future,” says Lill.

In light of the current crisis, the group took an unusual decision by immediately making the test results publicly available in the form of an open-source preprint. The publication was consulted more than 3,000 times during the first 48 hours alone. The Basel researchers hope that a larger number of research groups worldwide will test their proposals on the virus and initiate further trials. Normally, when it comes to drug design, the molecules of interest would be experimentally tested with other groups before the results were patented and published. The main focus of other ongoing coronavirus trials is currently on the usability of existing antiviral drugs or the realignment of other drugs.


Source: University of Basel

10.03.2020

Read all latest stories

Related articles

Photo

News • Pilot clinical trial

China to test targeted therapy for COVID-19

A University of British Columbia (UBC) researcher is part of an international team working with a biotechnology company on a pilot clinical trial of a potential new treatment for patients with severe…

Photo

News • Unifying disease dynamics

Covid-19: New insights into recovery after severe disease

Recovery from severe Covid-19 is characterized by a reduction of certain white blood cells and changes in the molecular regulation of the immune system, an international research team found.

Photo

News • Protein malformation

Covid-19: immune reaction may cause amyloid generation

In patients with serious and long-term Covid-19, disturbed blood coagulation is often observed. Now, Swedish researchers found a connection between harmful amyloid production and Covid-19 symptoms.

Related products

Sarstedt - COVID-19 virus diagnostics products

Saliva Collection

Sarstedt - COVID-19 virus diagnostics products

SARSTEDT AG & CO. KG
Zybio – Disposable Virus Sampling Tube

Sample Collection

Zybio – Disposable Virus Sampling Tube

Zybio Inc.
Beckman Coulter – SARS-CoV-2 Assays

Immunoassays

Beckman Coulter – SARS-CoV-2 Assays

Beckman Coulter Diagnostics
Lifotronic  SARS-CoV-2 Antibody Detection Kit

Immunoassays

Lifotronic SARS-CoV-2 Antibody Detection Kit

Lifotronic Technology Co., Ltd
Lifotronic – SARS-CoV-2 Antigen

Immunoassays

Lifotronic – SARS-CoV-2 Antigen

Lifotronic Technology Co., Ltd
Subscribe to Newsletter